Vaxart, Inc. - Common Stock (VXRT)
Frequently Asked Questions About Vaxart, Inc. - Common Stock (VXRT)
How can someone learn more about Vaxart, Inc.?
To learn more about Vaxart, Inc., individuals can visit the company's official website, where they can access information about its research programs, clinical trials, investor relations, and latest news. Additionally, following Vaxart on professional social media platforms can provide updates on its operations and developments.
How does Vaxart address safety in its vaccine development?
Vaxart prioritizes safety in its vaccine development process by adhering to stringent regulatory guidelines and conducting rigorous preclinical and clinical testing. The company aims to ensure that its oral vaccines are safe and well-tolerated through thorough evaluation of safety profiles before they are brought to the market.
How does Vaxart secure funding for its projects?
Vaxart secures funding through a combination of equity financing, collaborations, government grants, and partnerships with other biotech firms and institutions. This diverse approach to funding enables the company to support its research and development efforts while advancing its vaccine pipeline.
How does Vaxart's oral vaccine platform work?
Vaxart's oral vaccine platform employs a unique approach that incorporates viral vector technology to deliver antigens directly to the gut-associated lymphoid tissue. This method aims to elicit both systemic and mucosal immune responses, potentially providing robust and long-lasting protection against targeted pathogens.
Is Vaxart a publicly traded company?
Yes, Vaxart, Inc. is a publicly traded company, listed on the Nasdaq under the ticker symbol VXRT. This listing provides the company with access to capital markets and enables investors to buy and sell shares of the company.
What are Vaxart's recent achievements?
Vaxart has achieved several milestones in recent years, including the initiation of clinical trials for its vaccine candidates, successful completion of preclinical studies, and presentations at scientific conferences to share its findings. These achievements highlight the company's progress in vaccine development and its potential to address public health needs.
What clinical trials is Vaxart currently conducting?
Vaxart is currently conducting several clinical trials to evaluate the safety and efficacy of its oral vaccines. Ongoing trials include those for its norovirus vaccine candidates and its COVID-19 vaccine, which aim to assess the vaccines' ability to elicit immune responses in humans.
What does Vaxart, Inc. do?
Vaxart, Inc. is a biotechnology company focused on developing innovative oral vaccines based on its proprietary oral tablet platform. The company aims to provide accessible, stable, and effective vaccines that can be easily administered and stored, addressing global health challenges and improving vaccination rates.
What is the future outlook for Vaxart, Inc.?
The future outlook for Vaxart, Inc. appears promising, given its innovative approach to vaccine development and its potential to address significant unmet medical needs. As the company progresses through clinical trials and seeks to bring its oral vaccines to market, it aims to contribute to global health initiatives and expand its impact in the biotechnology space.
What is the primary technology used by Vaxart?
Vaxart primarily utilizes an oral vaccine platform that leverages its proprietary recombinant adenoviral vector technology. This platform allows for the development of vaccines that can be taken in pill form, which may enhance safety, efficacy, and ease of distribution compared to traditional injection-based vaccines.
What is the significance of the company's focus on oral vaccines?
The focus on oral vaccines is significant because it aims to overcome some of the limitations associated with traditional injectable vaccines, such as needle-phobia, storage difficulties, and logistical challenges in distribution. Oral vaccines can be easier to administer and store, potentially increasing vaccination rates and improving public health outcomes.
What makes Vaxart's technology unique?
Vaxart's technology is unique because it utilizes an oral delivery system based on recombinant adenoviral vectors. This innovative approach aims to enhance vaccine stability, ease of administration, and the ability to generate robust immune responses, setting it apart from traditional injectable vaccine methods.
What partnerships has Vaxart formed?
Vaxart has established partnerships with various organizations, including academic institutions and biotech companies, to further its research and development efforts. Collaborations often focus on advancing vaccine technologies and expanding clinical study capabilities.
What role do investors play in the growth of Vaxart?
Investors play a crucial role in the growth of Vaxart by providing the necessary capital to fund research and development initiatives, clinical trials, and operational activities. Through public offerings and other forms of investment, shareholders contribute to the company’s ability to pursue its strategic objectives and advance its pipeline.
What types of vaccines is Vaxart developing?
Vaxart is developing a variety of oral vaccines targeting several infectious diseases, including norovirus, seasonal and pandemic influenza, and COVID-19. The company aims to create vaccines that can stimulate robust immune responses and be safe and convenient for patients.
When was Vaxart, Inc. founded?
Vaxart, Inc. was founded in 2004. Since then, the company has grown and evolved, shifting its focus toward the development of oral vaccines and becoming a prominent player in the biotechnology industry.
Where is Vaxart, Inc. headquartered?
Vaxart, Inc. is headquartered in South San Francisco, California. This strategic location positions the company within a vibrant biotechnology ecosystem, granting access to a wealth of resources, collaboration opportunities, and a skilled workforce.
Who are the key executives at Vaxart?
Vaxart's leadership team consists of experienced professionals from diverse backgrounds in biotechnology and pharmaceuticals. The key executives include CEO and President, alongside senior leaders overseeing research and development, operations, and finance, who collectively drive the company’s strategic vision and operations.
Who are Vaxart's competitors in the vaccine industry?
Vaxart competes with various companies in the vaccine industry, including traditional biopharma companies that develop injectable vaccines and other innovative biotech firms focusing on oral vaccine technologies. Key competitors may include companies working on similar vaccine targets and those developing non-traditional vaccine delivery methods.
What is the current price of Vaxart, Inc. - Common Stock?
The current price of Vaxart, Inc. - Common Stock is 0.3500
When was Vaxart, Inc. - Common Stock last traded?
The last trade of Vaxart, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Vaxart, Inc. - Common Stock?
The market capitalization of Vaxart, Inc. - Common Stock is 53.19M
How many shares of Vaxart, Inc. - Common Stock are outstanding?
Vaxart, Inc. - Common Stock has 151.97M shares outstanding.